# Ocugen, Inc.: overview OCGN · Nasdaq · CIK 1372299 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ocgn.md) · [Financials](/companies/ocgn/financials.md) · [Filings](/companies/ocgn/filings.md) · [Insiders](/companies/ocgn/insiders.md) Latest reported revenue: [$1.5m](/filings/0001628280-26-054057.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054057). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.1](/filings/0001372299-25-000013.md) | [0.8 d](/filings/0001628280-26-014435.md) | [1.5](/filings/0001628280-26-032454.md) | [1.4](/filings/0001628280-26-054057.md) | [1.8](/filings/0001372299-25-000013.md) | [(0.2) d](/filings/0001628280-26-014435.md) | [1.5](/filings/0001628280-26-032454.md) | [1.5](/filings/0001628280-26-054057.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1166.5%)](/filings/0001372299-25-000013.md) | [(1811.5%) d](/filings/0001628280-26-014435.md) | [(979.1%)](/filings/0001628280-26-032454.md) | [(1004.7%)](/filings/0001628280-26-054057.md) | [(1006.0%)](/filings/0001372299-25-000013.md) | [8805.7% d](/filings/0001628280-26-014435.md) | [(1163.7%)](/filings/0001628280-26-032454.md) | [(1105.1%)](/filings/0001628280-26-054057.md) | | Net margin | % | [(1141.7%)](/filings/0001372299-25-000013.md) | [(1816.8%) d](/filings/0001628280-26-014435.md) | [(1036.5%)](/filings/0001628280-26-054057.md) | [(1073.5%)](/filings/0001628280-26-054057.md) | [(1144.5%)](/filings/0001372299-25-000013.md) | [9174.1% d](/filings/0001628280-26-014435.md) | [(1250.9%)](/filings/0001628280-26-054057.md) | [(1671.8%)](/filings/0001628280-26-054057.md) | | Diluted EPS | $ per share | not reported | not reported | [(0.05)](/filings/0001628280-26-032454.md) | [(0.05)](/filings/0001628280-26-054057.md) | not reported | not reported | [(0.06)](/filings/0001628280-26-032454.md) | [(0.07)](/filings/0001628280-26-054057.md) | | Free cash flow | $m | [(11.8) d](/filings/0001372299-25-000013.md) | [(10.4) d](/filings/0001628280-26-014435.md) | [(19.4)](/filings/0001628280-26-032454.md) | [(10.8) d](/filings/0001628280-26-054057.md) | [(13.0) d](/filings/0001372299-25-000013.md) | [(14.0) d](/filings/0001628280-26-014435.md) | [(21.8)](/filings/0001628280-26-032454.md) | [(12.2) d](/filings/0001628280-26-054057.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001628280-22-004085.md) | [2.5](/filings/0001628280-24-016378.md) | [6.0](/filings/0001628280-25-010271.md) | [4.1](/filings/0001628280-26-014435.md) | [4.4](/filings/0001628280-26-014435.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(3580.0%)](/filings/0001628280-24-016378.md) | [(1085.7%)](/filings/0001628280-25-010271.md) | [(1350.4%)](/filings/0001628280-26-014435.md) | [(1425.7%)](/filings/0001628280-26-014435.md) | | Net margin | % | not reported | [(3488.9%)](/filings/0001628280-24-016378.md) | [(1045.0%)](/filings/0001628280-25-010271.md) | [(1333.0%)](/filings/0001628280-26-014435.md) | [(1537.4%)](/filings/0001628280-26-014435.md) | | Diluted EPS | $ per share | [(0.30)](/filings/0001628280-23-005382.md) | [(0.40)](/filings/0001628280-24-016378.md) | [(0.26)](/filings/0001628280-24-016378.md) | not reported | not reported | | Free cash flow | $m | [(48.9)](/filings/0001628280-23-005382.md) | [(64.5)](/filings/0001628280-24-016378.md) | [(72.5)](/filings/0001628280-25-010271.md) | [(45.5)](/filings/0001628280-26-014435.md) | [(57.1)](/filings/0001628280-26-014435.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ocgn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $41.3m | 27,002,933 | | Added +19,697,954 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $32.8m | 21,469,307 | | Added +11,799,116 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.0m | 14,372,598 | | Added +568,487 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $21.3m | 13,943,252 | | Added +216,060 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.6m | 8,871,013 | | Added +4,643,909 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $10.2m | 6,666,666 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $7.9m | 5,177,508 | | Reduced −2,102,812 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $6.1m | 3,962,972 | | Unchanged | | [GMT Capital Corp](/funds/1106191.md) | 2026-06-30 | $5.4m | 3,505,398 | | Unchanged | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $5.2m | 3,410,257 | | Reduced −4,642,093 | ## Recent filings [All 875 filings](/companies/ocgn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 12:01 ET | [8-K](/filings/0001104659-26-115970.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-115970 | | 2026-10-15 | 01:22 ET | [8-K](/filings/0001104659-26-115921.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-115921 | | 2026-10-06 | 21:36 ET | [8-K](/filings/0001628280-26-065077.md) | 5.07 Shareholder vote results | 0001628280-26-065077 | | 2026-09-23 | 21:34 ET | [8-K](/filings/0001628280-26-063084.md) | 5.07 Shareholder vote results | 0001628280-26-063084 | | 2026-09-08 | 21:27 ET | [8-K](/filings/0001104659-26-105968.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-105968 | | 2026-08-06 | 16:15 ET | [10-Q](/filings/0001628280-26-054057.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054057 | | 2026-08-06 | 12:30 ET | [8-K](/filings/0001104659-26-091691.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091691 | | 2026-07-30 | 20:30 ET | [DEF 14A](/filings/0001140361-26-030258.md) | Proxy statement, period 2026-09-21 | 0001140361-26-030258 | | 2026-07-13 | 12:30 ET | [8-K](/filings/0001104659-26-082897.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-082897 | | 2026-06-11 | 21:19 ET | [8-K](/filings/0001104659-26-073015.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001104659-26-073015 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-014435.md), filed Mar 4, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3f797eda-f8eb-4c6a-af39-290b88daeff1) ## About the filer - CIK: 1372299 - Tickers: OCGN - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.